Filtered By:
Condition: Heart Failure
Drug: Tamoxifen
This page shows you your search results in order of date.
Order by Relevance | Date
Total 21 results found since Jan 2013.
RNA interference or small molecule inhibition of Runx1 in the border zone prevents cardiac contractile dysfunction following myocardial infarction
CONCLUSIONS: Our results confirm the translational potential of RUNX1 as a novel therapeutic target in myocardial infarction, with wider opportunities for use across a range of cardiac diseases where RUNX1 drives adverse cardiac remodelling.PMID:37433039 | DOI:10.1093/cvr/cvad107
Source: Cell Research - July 11, 2023 Category: Cytology Authors: Tamara P Martin Eilidh A MacDonald Ashley Bradley Holly Watson Priyanka Saxena Eva A Rog-Zielinska Anmar Raheem Simon Fisher Ali Ali Mohamed Elbassioni Ohood Almuzaini Catriona Booth Morna Campbell Alex Riddell Pawel Herzyk Karen Blyth Colin Nixon Lorena Source Type: research
Cardiomyocyte p38 MAPK α suppresses a heart-adipose tissue-neutrophil crosstalk in heart failure development
Basic Res Cardiol. 2022 Oct 7;117(1):48. doi: 10.1007/s00395-022-00955-2.ABSTRACTAlthough p38 MAP Kinase α (p38 MAPKα) is generally accepted to play a central role in the cardiac stress response, to date its function in maladaptive cardiac hypertrophy is still not unambiguously defined. To induce a pathological type of cardiac hypertrophy we infused angiotensin II (AngII) for 2 days via osmotic mini pumps in control and tamoxifen-inducible, cardiomyocyte (CM)-specific p38 MAPKα KO mice (iCMp38αKO) and assessed cardiac function by echocardiography, complemented by transcriptomic, histological, and immune cell analysis. ...
Source: Cell Research - October 7, 2022 Category: Cytology Authors: Katharina Bottermann Lisa Kalfhues Rianne Nederlof Anne Hemmers Lucia M Leitner Vici Oenarto Jana Nemmer Mirjam Pfeffer Vidisha Raje Rene Deenen Patrick Petzsch Heba Zabri Karl K öhrer Andreas S Reichert Maria Grandoch Jens W Fischer Diran Herebian Johan Source Type: research
Fibroblast GSK-3 α Promotes Fibrosis via RAF-MEK-ERK Pathway in the Injured Heart
CONCLUSIONS: GSK-3α-mediated MEK-ERK activation is a critical profibrotic signaling circuit in the injured heart, which operates independently of the canonical TGF-β1-SMAD3 pathway. Therefore, strategies to inhibit the GSK-3α-MEK-ERK signaling circuit could prevent adverse fibrosis in diseased hearts.PMID:36052698 | DOI:10.1161/CIRCRESAHA.122.321431
Source: Circulation Research - September 2, 2022 Category: Cardiology Authors: Prachi Umbarkar Sultan Tousif Anand P Singh Joshua C Anderson Qinkun Zhang Michelle D Tallquist James Woodgett Hind Lal Source Type: research
Prolonged cardiac NR4A2 activation causes dilated cardiomyopathy in mice
In this study, we aimed to interrogate the consequences of cardiac NR4A2 up-regulation under normal conditions and in response to pressure overload. In mice, tamoxifen-dependent, cardiomyocyte-restricted overexpression of NR4A2 led to cardiomyocyte hypertrophy, left ventricular dilation, heart failure, and death within 40 days. Chronic NR4A2 induction also precipitated cardiac decompensation during transverse aortic constriction (TAC)-induced pressure overload. Mechanistically, NR4A2 caused adult cardiac myocytes to return to a fetal-like phenotype, with a switch to glycolytic metabolism and disassembly of sarcomeric struc...
Source: Cell Research - July 1, 2022 Category: Cytology Authors: Sadia Ashraf Heinrich Taegtmeyer Romain Harmancey Source Type: research
Cardiomyocyte BRAF and type 1 RAF inhibitors promote cardiomyocyte and cardiac hypertrophy in mice in vivo
In conclusion, BRAF potentially plays an important role in human failing hearts, activation of BRAF is sufficient to induce hypertrophy, and Type 1 RAF inhibitors promote hypertrophy via the 'RAF paradox'. Cardiac hypertrophy resulting from these interventions was not associated with pathological features, suggesting that Type 1 RAF inhibitors may be useful to boost cardiomyocyte function.PMID:35147166 | DOI:10.1042/BCJ20210615
Source: The Biochemical Journal - February 11, 2022 Category: Biochemistry Authors: Angela Clerk Daniel N Meijles Michelle A Hardyman Stephen J Fuller Sonia P Chothani Joshua J Cull Susanna T E Cooper Hajed O Alharbi Konstantinos Vanezis Leanne E Felkin Thomais Markou Samuel J Leonard Spencer W Shaw Owen J L Rackham Stuart A Cook Peter E Source Type: research
Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort study
CONCLUSION: Our results indicate an increased risk for ischemic heart disease and arrhythmia in patients treated for more than four years with AIs. This should be considered in the risk-benefit assessment concerning endocrine therapy.PMID:34265496 | DOI:10.1016/j.breast.2021.07.004
Source: Breast - July 15, 2021 Category: Cancer & Oncology Authors: Maria Sund Miguel Garcia-Argibay Hans Garmo Johan Ahlgren Anna-Karin Wennstig Irma Fredriksson Henrik Lindman Antonis Valachis Source Type: research
